Using the Commercial Label to Map the Way for In-Use Study Design: Poster Presented at PDA Week 2026

Area of Science:

• Pharmaceutical Sciences
• Drug Development
• Regulatory Science

Background:

• Commercial prescribing information is crucial for drug product development.
• Study design must anticipate real-world usage and regulatory requirements.
• Ensuring drug product stability and appropriate storage is vital for patient safety and efficacy.

Purpose of the Study:

• To demonstrate how intended commercial prescribing information can strategically guide drug product study design.
• To align study protocols (in-use, short-term, long-term stability) with end-user needs and regulatory expectations.
• To highlight practical approaches for patient-centric study strategies.

Main Methods:

• The study emphasizes aligning drug product study design with intended commercial labeling.
• It advocates for integrating real-world use scenarios and regulatory guidelines early in the process.
• Cross-functional collaboration and practical examples are presented to illustrate the methodology.

Main Results:

• Aligning study design with label intent streamlines the drug development process.
• This approach purposefully guides Chemistry, Manufacturing, and Controls (CMC) label content.
• Robust, patient-centric study strategies are developed, ensuring product meets storage and handling needs.

Conclusions:

• Intended commercial prescribing information should serve as a strategic anchor for drug product studies.
• Early consideration of label intent optimizes study design, development timelines, and CMC content.
• This patient-centric approach ensures the final drug product is suitable for end-users.